Elesclomol

Vadadustat demonstrated a clinically meaningful safety outcome benefit in U.S. patients with anemia due to CKD on dialysis utilizing TIW dosing regimen WALTHAM, Mass., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease announced that U.S. Renal Care (USRC), the nation’s largest privately held and fastest-growing kidney care provider, presented data from the Vafseo Outcomes In Center Experience (VOICE) trial during a late-breaking session at American Society of Nephrology Kidney Week 2026 (ASN Kidney Week). The presentation highlighted findings of significantly improved safety outcomes in patients treated with vadadustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) dosed three times weekly (TIW) versus an erythropoiesis-stimulating agent (ESA). Additional data showed more stable hemoglobin control and fewer serious adverse events in the patients treated with vadadustat. In March 2024, Vafseo ® (vadadustat), was approved by the U.S. Food and Drug Administration for the treatment of anemia due to chronic kidney disease in adults who have been receiving dialysis for at least three months, and it has been available in the U.S. since January 2025. Vafseo is approved for once-daily administration. There are no other oral HIF-PHIs to treat anemia in the market or in development in the U.S. “The VOICE trial was designed to test the hypothesis that an innovative treatment for anemia in patients on dialysis could deliver more than just hemoglobin management, but rather could deliver clinically meaningful outcomes versus ESA,” said Geoffrey A. Block, M.D., FASN, Associate Chief Medical Officer and Senior Vice President, Clinical Research & Medical Affairs for USRC. “The VOICE trial data demonstrated that treatment with vadadustat resulted in a statistically significant reduction in the primary composite endpoint of all-cause mortality and hospitalization, with the results driven by a reduction in hospitalization, versus patients treated with ESA. Further, we observed that patients treated with vadadustat experienced fewer high hemoglobin excursions and lower ESA rescue versus patients treated with ESA, both clinically meaningful outcomes. We’re extremely pleased that the data validated our understanding of the potential clinical benefit of vadadustat, which we believe positions vadadustat to become a new standard of care. We are grateful to the thousands of patient volunteers who have participated, as well as, the USRC Kidney Research team, investigators, and the staff at participating facilities, all without whom we would not have been able to complete this meaningful trial.” The VOICE trial enrolled 2,116 patients and was designed as a randomized, open-label, active-controlled, noninferiority trial sponsored by USRC to measure the safety of vadadustat administered TIW versus standard-of-care ESA using a hierarchical composite endpoint of mortality and hospitalization rates. The trial demonstrated a win odds of 1.16 (95% confidence interval (CI) 1.06, 1.28, p=0.0016), establishing non-inferiority and superiority of the primary composite endpoint. Further, the data demonstrated: The hospitalization rate was 10% lower in patients treated with vadadustat versus ESA. There was a statistically significant decrease in hospitalization rate with vadadustat versus ESA (111.1 versus 123.1 hospitalizations per 100 patient-years, incidence rate ratio of 0.90 (95% CI, 0.82, 0.99). There was no statistically significant difference between mortality rates with vadadustat versus ESA (8.8% versus 8.8% per 100 patient-years, incidence rate ratio of 1.00 (95% CI 0.72, 1.39). Exposure-adjusted serious adverse events were lower with vadadustat versus ESA. Patients treated with vadadustat experienced 121.5 events per 100 patient-years compared to 134.2 events per 100 patient-years for patients treated with ESA. Vadadustat improved hemoglobin control versus ESA. High hemoglobin (HgB) excursions were less common in patients treated with vadadustat compared to ESA. The reduction in excursions for patients treated with vadadustat versus ESA were as follows: a 64% reduction in the odds of a HgB above 12 g/dL (29.6% vs. 51.2%, p<0.0001), a 57% reduction in the odds of a HgB above 13 g/dL (6.4% vs. 12.7%, p<0.0001), and 61% reduction in the odds of a HgB above 14 g/dL (1.6% vs. 3.2%, p=0.0044). There was no overall difference in low excursions (below 9, 8, or 7 g/dL). The odds of ESA rescue were 28% less likely with vadadustat versus ESA (44.6% vs. 52.8%, p=0.0006). About the VOICE Trial The Vafseo Outcomes In-Center Experience (VOICE) trial, a collaborative trial between U.S. Renal Care and Akebia Therapeutics, is an investigator-initiated, multi-center, randomized, open-label, active-controlled, non-inferiority trial of the safety of vadadustat administered three times per week for the treatment of anemia in in-center hemodialysis patients with end stage kidney disease. The primary endpoint is a composite hierarchical endpoint of all-cause mortality and all-cause hospitalization, analyzed by the win odds method. The secondary endpoints are all-cause hospitalization and all-cause mortality. Please refer to NCT06520826 on for more information about the VOICE trial. About U.S. Renal Care U.S. Renal Care is the largest privately held and fastest-growing dialysis provider in the nation. We partner with nephrologists to care for more than 37,000 people living with kidney disease across 32 states, offering in-center and home dialysis options that support each patient’s unique lifestyle and care needs. U.S. Renal Care leads the dialysis industry with the highest percentage of CMS 4- and 5-star rated centers for patient experience and quality of care. U.S. Renal Care’s Kidney Research team designs and conducts clinical trials, spanning across academic collaboration, investigator-initiated research, industry-sponsored research, and federally-funded research. Since 2000, U.S. Renal Care has grown through clinical excellence, innovation and a shared commitment to improving the lives of people with kidney disease. Visit USRenalCare.com to learn more. About Akebia Therapeutics Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Waltham, Massachusetts. For more information, please visit our website at , which does not form a part of this release. About Vafseo ® (vadadustat) tablets Vafseo ® (vadadustat) tablets is a once-daily oral hypoxia-inducible factor prolyl hydroxylase inhibitor that activates the physiologic response to hypoxia to stimulate endogenous production of erythropoietin, increasing hemoglobin and red blood cell production to manage anemia. Vafseo is approved for use in 37 countries. INDICATION VAFSEO is indicated for the treatment of anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least three months. Limitations of Use VAFSEO has not been shown to improve quality of life, fatigue, or patient well-being. VAFSEO is not indicated for use: As a substitute for red blood cell transfusions in patients who require immediate correction of anemia. In patients with anemia due to CKD not on dialysis. IMPORTANT SAFETY INFORMATION about VAFSEO (vadadustat) tablets WARNING: INCREASED RISK OF DEATH, MYOCARDIAL INFARCTION, STROKE, VENOUS THROMBOEMBOLISM, and THROMBOSIS OF VASCULAR ACCESS. VAFSEO increases the risk of thrombotic vascular events, including major adverse cardiovascular events (MACE). Targeting a hemoglobin level greater than 11 g/dL is expected to further increase the risk of death and arterial and venous thrombotic events, as occurs with erythropoietin stimulating agents (ESAs), which also increase erythropoietin levels. No trial has identified a hemoglobin target level, dose of VAFSEO, or dosing strategy that does not increase these risks. Use the lowest dose of VAFSEO sufficient to reduce the need for red blood cell transfusions. CONTRAINDICATIONS Known hypersensitivity to VAFSEO or any of its components Uncontrolled hypertension WARNINGS AND PRECAUTIONS Increased Risk of Death, Myocardial Infarction (MI), Stroke, Venous Thromboembolism, and Thrombosis of Vascular Access A rise in hemoglobin (Hb) levels greater than 1 g/dL over 2 weeks can increase these risks. Avoid in patients with a history of MI, cerebrovascular event, or acute coronary syndrome within the 3 months prior to starting VAFSEO. Targeting a Hb level of greater than 11 g/dL is expected to further increase the risk of death and arterial and venous thrombotic events. Use the lowest effective dose to reduce the need for red blood cell (RBC) transfusions. Adhere to dosing and Hb monitoring recommendations to avoid excessive erythropoiesis. Hepatotoxicity Hepatocellular injury attributed to VAFSEO was reported in less than 1% of patients, including one severe case with jaundice. Elevated serum ALT, AST, and bilirubin levels were observed in 1.8%, 1.8%, and 0.3% of CKD patients treated with VAFSEO, respectively. Measure ALT, AST, and bilirubin before treatment and monthly for the first 6 months, then as clinically indicated. Discontinue VAFSEO if ALT or AST is persistently elevated or accompanied by elevated bilirubin. Not recommended in patients with cirrhosis or active, acute liver disease. Hypertension Worsening of hypertension was reported in 14% of VAFSEO and 17% of darbepoetin alfa patients. Serious worsening of hypertension was reported in 2.7% of VAFSEO and 3% of darbepoetin alfa patients. Cases of hypertensive crisis, including hypertensive encephalopathy and seizures, have also been reported in patients receiving VAFSEO. Monitor blood pressure. Adjust anti-hypertensive therapy as needed. Seizures Seizures occurred in 1.6% of VAFSEO and 1.6% of darbepoetin alfa patients. Monitor for new-onset seizures, premonitory symptoms, or change in seizure frequency. Gastrointestinal (GI) Erosion Gastric or esophageal erosions occurred in 6.4% of VAFSEO and 5.3% of darbepoetin alfa patients. Serious GI erosions, including GI bleeding and the need for RBC transfusions, were reported in 3.4% of VAFSEO and 3.3% of darbepoetin alfa patients. Consider this risk in patients at increased risk of GI erosion. Advise patients about signs of erosions and GI bleeding and urge them to seek prompt medical care if present. Serious Adverse Reactions in Patients with Anemia Due to CKD and Not on Dialysis The safety of VAFSEO has not been established for the treatment of anemia due to CKD in adults not on dialysis and its use is not recommended in this setting. In large clinical trials in adults with anemia of CKD who were not on dialysis, an increased risk of mortality, stroke, MI, serious acute kidney injury, serious hepatic injury, and serious GI erosions was observed in patients treated with VAFSEO compared to darbepoetin alfa. Malignancy VAFSEO has not been studied and is not recommended in patients with active malignancies. Malignancies were observed in 2.2% of VAFSEO and 3.0% of darbepoetin alfa patients. No evidence of increased carcinogenicity was observed in animal studies. ADVERSE REACTIONS The most common adverse reactions (occurring at ≥ 10%) were hypertension and diarrhea. DRUG INTERACTIONS Iron supplements and iron-containing phosphate binders: Administer VAFSEO at least 1 hour before products containing iron. Non-iron-containing phosphate binders : Administer VAFSEO at least 1 hour before or 2 hours after non-iron-containing phosphate binders. BCRP substrates : Monitor for signs of substrate adverse reactions and consider dose reduction. Statins : Monitor for statin-related adverse reactions. Limit the daily dose of simvastatin to 20 mg and rosuvastatin to 5 mg. USE IN SPECIFIC POPULATIONS Pregnancy: May cause fetal harm. A pregnancy exposure registry is available to monitor outcomes in women exposed to VAFSEO during pregnancy. Report pregnancies to 1-844-445-3799. Lactation: Breastfeeding not recommended until two days after the final dose. Hepatic Impairment : Not recommended in patients with cirrhosis or active, acute liver disease. Please note that this information is not comprehensive. Please click here for the Full Prescribing Information, including BOXED WARNING and Medication Guide. Forward-Looking Statements Statements in this press release regarding Akebia Therapeutics, Inc.'s ("Akebia's") strategy, plans, prospects, expectations, beliefs, intentions and goals are forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, as amended, and include, but are not limited to: statements made by Geoffrey A. Block in this press release, including the hypothesis that vadadustat could deliver hemoglobin management as well as clinically meaningful outcomes versus ESA, beliefs that patients experiencing fewer high hemoglobin excursions and lower ESA rescue when treated with vadadustat versus ESA as observed in the VOICE trial represent clinically meaningful outcomes, beliefs and understandings regarding the potential clinical benefit of vadadustat and the extent it is positioned to become a new standard of care. The terms "intend," "believe," "plan," "goal," "potential," "anticipate,” "estimate," “target,” “predict,” "expect," "future," “may,” "will," “could,” "continue," derivatives of these words, and similar references are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results, performance or experience may differ materially from those expressed or implied by any forward-looking statement as a result of various risks, uncertainties and other factors, including, but not limited to, risks associated with: the potential therapeutic benefits, safety profile, and effectiveness of vadadustat; risks and uncertainties related to Akebia’s ongoing and planned research and development activities, including initiating, conducting or completing preclinical studies and clinical trials and the timing of such preclinical studies and clinical trials; the results of Akebia’s preclinical studies and clinical trials, including that initial, preliminary, interim or retrospective data, analysis or results may not be replicated in, or predictive of, final analyses or results of future preclinical or clinical data, analyses or results or that such analysis or results may not support further development of such product candidates; Akebia’s ability to initiate and enroll patients in its clinical trials; decisions made by health authorities, such as the FDA, with respect to regulatory filings and other interactions; the potential demand and market potential and acceptance of, as well as coverage and reimbursement related to Akebia’s commercial products, including estimates regarding the potential market opportunity; the competitive landscape for Akebia’s commercial products, including generic entrants and the timing thereof; Akebia’s ability to obtain and maintain patent protection on its products and product candidates, and to successfully defend these patents against third-party challenges; Akebia’s ability to attract and retain qualified personnel; Akebia's ability to achieve and maintain profitability and to maintain operating expenses consistent with its operating plan; Akebia’s revenue and that its financial results from prior periods may not be indicative of future results; manufacturing, supply chain and quality matters and any recalls, write-downs, impairments or other related consequences or potential consequences; early termination of any of Akebia's collaborations; and changes in the geopolitical environment and uncertainty surrounding U.S. trade policy on tariffs. Other risks and uncertainties include those identified under the heading "Risk Factors" in Akebia's most recent Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission (SEC), and other filings that Akebia may make with the SEC in the future. These forward-looking statements (except as otherwise noted) speak only as of the date of this press release, and, except as required by law, Akebia does not undertake, and specifically disclaims, any obligation to update any forward-looking statements contained in this press release. Akebia Therapeutics ® and Vafseo ® are registered trademarks of Akebia Therapeutics, Inc. Akebia Therapeutics Contact Mercedes Carrasco mcarrasco@akebia.com

期刊：Journal of Hematology & Oncology 影响因子：47.8 客户单位：武汉大学 文章作者：武汉大学医学研究院邓晓颐、博士邓在冬、华中科技大学协和肿瘤科朱斌为共同第一作者。武汉大学中南医院教授陈宁南、教授俞雁寻，合武汉大学中南医院肿瘤科主任、教授医生刘羽为本文共同通讯作者。 研究背景 肿瘤代谢应激与免疫原性细胞死亡的交汇 肿瘤免疫治疗的核心挑战之一，是如何将免疫学上“冷”的肿瘤转化为“热”的肿瘤。免疫原性细胞死亡（ICD）是一种特殊的细胞死亡形式，能够释放损伤相关分子模式（DAMPs），激活树突状细胞，促进抗原呈递，最终激活 CD8+ T 细胞介导的抗肿瘤免疫。然而，肿瘤细胞如何逃逸 ICD，以及代谢应激如何调控这一过程，仍不清楚。 铁死亡和铜死亡是近年来备受关注的两种新型细胞死亡方式。铁死亡以脂质过氧化和铁依赖性活性氧（ROS）积累为特征；铜死亡则依赖于铜离子诱导的线粒体应激和蛋白质毒性。两者都与 ROS 稳态密切相关。谷胱甘肽（GSH）是细胞内最主要的抗氧化分子，而谷胱甘肽二硫还原酶（GSR）是维持 GSH 还原状态的关键酶。GSH/GSR 轴在肿瘤耐药和代谢应激中扮演核心角色，但它是否以及如何调控铁死亡和铜死亡的免疫原性，尚属未知。 武汉大学中南医院教授陈宁南、教授俞雁寻联合武汉大学中南医院肿瘤科主任、教授医生刘羽团队，本研究首次系统揭示了GSR作为铁死亡和铜死亡免疫原性的核心调控节点，阐明了GSR缺失通过放大ROS积累、激活cGAS-STING通路，最终增强抗肿瘤免疫的完整分子机制。  >点击跳转< 该研究以《Glutathione reductase deficiency potentiates the immunogenicity of ferroptosis and cuproptosis via amplified reactive oxygen species accumulation and cGAS-STING pathway activation》为题，于北京时间2026年9月1日发表于《血液学与肿瘤学杂志》。该研究不仅深化了人类对代谢应激如何调控抗肿瘤免疫的理解，也为开发代谢干预联合免疫治疗的新策略提供了全新思路。 核心实验发现与机制解析 01. 现象关联 GSR 是铁死亡和铜死亡免疫原性的关键调控因子 本研究首先通过全基因组 CRISPR 筛选，在多种肿瘤细胞系中鉴定出 GSR 是铁死亡和铜死亡敏感性的关键调控基因。GSR 缺失显著增强了肿瘤细胞对铁死亡诱导剂（如 Erastin、RSL3）和铜死亡诱导剂（如 Elesclomol、Disulfiram）的敏感性。 值得注意的是，GSR 缺失不仅促进细胞死亡，还显著增强了死亡的免疫原性——表现为细胞表面钙网蛋白（CRT）暴露增加、HMGB1 释放增多、ATP 分泌升高，这些都是 ICD 的经典标志。 图1 GSR 缺失增强铁死亡和铜死亡中的免疫激活 02. 功能确证 GSR 缺失通过 ROS 放大激活 cGAS-STING 通路 为了验证 GSR 缺失的免疫原性效应，本研究在多种肿瘤模型中进行了功能实验。 在体外 GSR 敲除或抑制剂处理导致细胞内 ROS 水平显著升高，伴随脂质过氧化产物 4-HNE 和 MDA 的积累。ROS 的过度积累导致线粒体 DNA（mtDNA）泄漏至细胞质，激活 cGAS-STING 通路，诱导 IFN-β 和 CXCL10 等干扰素刺激基因的表达。 图2 GSR 缺失增强线粒体DNA释放和STING通路激活 在体内 GSR 缺失的肿瘤细胞在免疫 competent 小鼠中生长显著受抑制。GSR 缺失肿瘤中 CD8+ T 细胞浸润显著增加，PD-1 表达降低，提示 T 细胞耗竭减轻。 图3 GSR 缺失诱导的肿瘤抑制通过铁死亡和铜死亡发生 03. 机制揭秘 ROS 放大驱动 mtDNA 释放与 STING 激活 GSR 缺失如何激活 cGAS-STING？本研究通过一系列实验揭示了这一机制。 ROS 是核心信使 GSR 缺失导致 GSH 还原能力下降，ROS 清除受阻，细胞内 ROS 水平显著升高。使用 ROS 清除剂 N-乙酰半胱氨酸（NAC）可以完全逆转 GSR 缺失诱导的 STING 激活和 ICD 标志物释放。 图4 GSR 缺失以 GSR 依赖的方式增强抗肿瘤疗效 mtDNA 是 STING 的配体 ROS 过度积累导致线粒体膜通透性增加，mtDNA 泄漏至细胞质。细胞质 mtDNA 被 cGAS 识别，激活 STING-TBK1-IRF3 通路。敲低 cGAS 或 STING 可显著抑制 GSR 缺失诱导的 IFN-β 分泌和 ICD。 与铁死亡/铜死亡的关联 铁死亡诱导剂和铜死亡诱导剂均通过不同机制增加 ROS。GSR 缺失放大了这一效应，使 ROS 积累超过细胞抗氧化阈值，从而触发 mtDNA 释放和 STING 激活。这解释了为什么 GSR 缺失同时增强铁死亡和铜死亡的免疫原性——两者共享 ROS 放大的共同通路。 图5 GSR 缺失与免疫检查点抑制剂（ICI）治疗产生协同作用 04. 网络特性 GSH/GSR 轴与 STING 通路的协同放大 本研究进一步发现，GSR 缺失不仅通过 ROS 激活 STING，STING 通路的激活还反过来进一步抑制 GSH 合成，形成正反馈放大环路。这种“ROS-STING-GSH”的相互调控网络，使得 GSR 缺失的肿瘤细胞陷入“免疫原性死亡-免疫激活”的良性循环。 研究成果总结 一个全新的代谢-免疫调控范式 本研究系统性地揭示了 GSH/GSR 代谢轴作为铁死亡和铜死亡免疫原性核心调控因子的分子机制。其核心逻辑如下： “ROS 放大 → mtDNA 释放 → cGAS-STING 激活 → ICD 增强 → T 细胞浸润 → 肿瘤抑制” 图6 GSR 缺失连接铁死亡、铜死亡与 cGAS-STING 介导的免疫原性细胞死亡的模型示意图 GSR 缺失导致 GSH 还原能力下降，ROS 清除受阻，ROS 水平升高。ROS 过度积累导致线粒体损伤和 mtDNA 泄漏，激活 cGAS-STING 通路。STING 激活诱导 I 型干扰素分泌，促进树突状细胞成熟和抗原呈递，增强 CD8⁺ T 细胞浸润和杀伤功能。同时，STING 激活进一步抑制 GSH 合成，形成正反馈放大环路。 该研究将 GSH/GSR 轴从单纯的抗氧化代谢节点，提升为肿瘤免疫原性调控的核心执行者，为代谢干预联合免疫治疗提供了全新策略。 研究的创新与突破 ① 概念创新 首次将 GSH/GSR 代谢轴确立为铁死亡和铜死亡免疫原性的共同调控节点，打破了以往将铁死亡和铜死亡视为独立死亡通路的认知。 ② 机制创新 揭示了“ROS 放大 → mtDNA 释放 → cGAS-STING 激活”这一代谢-免疫信号转导通路，为非经典 ICD 机制提供了清晰的分子模型。 ③ 系统特性创新 发现了 GSH/GSR 轴与 STING 通路之间的正反馈放大网络，解释了代谢干预如何将免疫抑制性肿瘤转化为免疫激活状态。 ④ 转化创新 GSR 抑制剂与免疫检查点阻断的联合策略在多种肿瘤模型中显示协同效应，为临床转化提供了临床前证据。 未来临床应用潜力与展望 这项基础研究的发现，为肿瘤免疫治疗带来了极具潜力的转化前景： 新型免疫治疗联合策略： GSR 抑制剂有望成为免疫检查点阻断的增效剂，将“冷肿瘤”转化为“热肿瘤”，扩大免疫治疗受益人群。 代谢标志物指导的精准治疗： GSR 表达水平或 GSH/GSSG 比值，有望成为预测免疫治疗响应的新型生物标志物。 铁死亡/铜死亡诱导剂的优化： 基于 GSR 缺失增强免疫原性的机制，未来可开发靶向 GSH/GSR 轴的小分子药物，与铁死亡或铜死亡诱导剂联合使用。 跨瘤种应用： GSR 在多种肿瘤中高表达，其抑制策略可能具有广谱抗肿瘤免疫激活潜力。 总之，本研究不仅深刻改变了我们对代谢应激如何调控抗肿瘤免疫的认知，更架起了一座从基础代谢研究通往临床免疫治疗改进的桥梁。 ABclonal 助力产品 ABclonal 为关键因子 AIM3、IRF3、p-IRF3、TBK1、cGAS、STING、p-STING 等关键研究因子提供助力，期望未来能有更多依托 ABclonal 优质产品及技术支持的研究，在肿瘤代谢与免疫治疗领域收获更为丰富的成果。 ABclonal重组单抗专项支持计划 一、ABclonal超级单抗敢于与全球质量最佳抗体正面PK 我们不惧对比，因为我们用数据说话，只为让您用上真正世界一流的抗体工具 更清晰的数据图：经KO验证特异性高，因此信噪比更高，背景更干净  更强的信号：亲和力高，低丰度蛋白也能轻松检出 更稳的表现：重组工艺，批次间一致性高，保证了您每一次实验结果的可重复性； 更高的性价比：多物种多应用，令人惊叹的稀释比，极致节省成本； 二、“超级单抗，真好用”是客户的真实感受 一次就成功，才是真好用, 结果可复现，才是真好用, 性价比超高，才是真好用, 数据可发表，才是真好用, 选择ABclonal超级单抗，让它们成为你实验的定心丸，从容应对科研路上的每一次挑战。 END ABclonal 公司简介 爱博泰克生物科技有限公司（简称：爱博泰克，ABclonal）成立于2011年，作为生命科学解决方案的提供商，旨在为全球生命科学工作者提供更好的产品与服务。公司主营业务包括抗体和分子酶试剂、生命科学仪器、药物发现CRO服务等，服务用户涵盖生命科学基础研究、转化研究、生物医药、精准医疗、体外诊断等多个领域。 ABclonal总部位于中国武汉，现有波士顿研发中心、上海诊断与科研分子酶研发中心以及武汉光谷诊断与免疫研发和生产中心。ABclonal业务遍布全球，在美国波士顿、德国、北京、天津、济南、西安、上海、武汉、南京、杭州、合肥、长沙、成都、重庆、广州和厦门建立直销团队，签约代理商近100家，覆盖全球40多个国家与地区。在过去的10年中，全球有超过100,000客户选择ABclonal。